Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to Sofia Maione born during COVID-19 outbreak.

Author: Casillo GM, Mansour AA, Raucci F, Saviano A, Mascolo N, Iqbal AJ, Maione F.

Source: Pharmacological Research

Year: 2020

Comment:

Abstract / Excerpt:

Since 2003, outbreaks of Coronavirus have caused multiple public health epidemics including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The first case of infection in response to a new strain of Coronaviridae, designated Coronavirus disease-19 (COVID-19) was recorded in Wuhan, China [1]. This virus appears to be weaker than SARS, in terms of pathogenesis but more sustained in its transmission behavior [2]. COVID-19 is transmittedthrough droplet inhalation, saliva, nasal and mucous membranes of eyes. Symptoms include fever, continuous coughing and shortness of breath.

Citation: Casillo GM, Mansour AA, Raucci F, Saviano A, Mascolo N, Iqbal AJ, Maione F. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to Sofia Maione born during COVID-19 outbreak. Pharmacological Research. 2020